Three-dimensional navigator coronary MRA with the aid of a blood pool agent in pigs: Improved image quality with inclusion of the contrast agent first-pass

2003 ◽  
Vol 18 (4) ◽  
pp. 502-506 ◽  
Author(s):  
Martijn S. Dirksen ◽  
Theodorus A.M. Kaandorp ◽  
Hildo J. Lamb ◽  
J. Doornbos ◽  
Claire Corot ◽  
...  
Keyword(s):  
Image Quality ◽  
Contrast Agent ◽  
Three Dimensional ◽  
Blood Pool ◽  
Blood Pool Agent ◽  
Coronary Mra ◽  
First Pass

scholarly journals High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol

2021 ◽  
Author(s):  
Puja Shahrouki ◽  
Sarah N. Khan ◽  
Takegawa Yoshida ◽  
Paul J. Iskander ◽  
Shahnaz Ghahremani ◽  
...  
Keyword(s):  
High Resolution ◽  
Image Quality ◽  
Contrast Agent ◽  
Adverse Reactions ◽  
Interobserver Agreement ◽  
Three Dimensional ◽  
Vena Cava ◽  
Blood Pool ◽  
Mr Venography ◽  
Venous Signal

Abstract Background Gadofosveset is a gadolinium-based blood pool contrast agent that was approved by the United States Food and Drug Administration in 2008. Its unanticipated withdrawal from production in 2016 created a void in the blood pool agent inventory and highlighted the need for an alternative agent with comparable imaging properties. Objective The purpose of our study is to compare the diagnostic image quality, vascular contrast-to-noise ratio (CNR) and temporal signal characteristics of gadofosveset trisodium and ferumoxytol at similar molar doses for high-resolution, three-dimensional (3-D) magnetic resonance (MR) venography in children. Materials and methods The medical records and imaging data sets of patients who underwent high-resolution 3-D gadofosveset-enhanced MR venography (GE-MRV) or ferumoxytol-enhanced MR venography (FE-MRV) were retrospectively reviewed. Two groups of 20 pediatric patients (age- and weight-matched with one patient common to both groups; age range: 2 days–15 years) who underwent high-resolution 3-D GE-MRV or FE-MRV at similar molar doses were identified and analyzed. Qualitative analysis of image quality and vessel definition was performed by two blinded pediatric radiologists. Interobserver agreement was assessed with the AC1 (first-order agreement coefficient) statistic. Signal-to-noise ratio (SNR) and CNR of the inferior vena cava and aorta were measured in the steady-state venous phase. Medical records were retrospectively reviewed for any adverse reactions associated with either contrast agent. Results Measured SNR and CNR of the inferior vena cava were higher for FE-MRV than GE-MRV (P = 0.034 and P < 0.001, respectively). The overall image quality score and individual vessel scores of FE-MRV were equal to or greater than GE-MRV (P = 0.084), with good interobserver agreement (AC1 = 0.657). The venous signal on FE-MRV was stable over the longest interval measured (1 h, 13 min and 46 s), whereas venous signal on GE-MRV showed more variability and earlier loss of signal. No adverse reactions were noted in any patient with either contrast agent. Conclusion Ferumoxytol produces more uniform and stable enhancement throughout the entire venous circulation in children than gadofosveset, offering a wider time window for optimal image acquisition. FE-MRV offers a near-ideal approach to high-resolution venography in children at all levels of anatomical complexity.

scholarly journals Contrast-Enhanced Magnetic Resonance Angiography Using a Novel Elastin-Specific Molecular Probe in an Experimental Animal Model

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Carolin Reimann ◽  
Julia Brangsch ◽  
Jan Ole Kaufmann ◽  
Lisa C. Adams ◽  
David C. Onthank ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Image Quality ◽  
Magnetic Resonance Angiography ◽  
Contrast Agent ◽  
Mr Angiography ◽  
Molecular Probe ◽  
Time Resolved ◽  
Clinical Dose ◽  
Contrast Enhanced ◽  
First Pass

Objectives. The aim of this study was to test the potential of a new elastin-specific molecular agent for the performance of contrast-enhanced first-pass and 3D magnetic resonance angiography (MRA), compared to a clinically used extravascular contrast agent (gadobutrol) and based on clinical MR sequences. Materials and Methods. Eight C57BL/6J mice (BL6, male, aged 10 weeks) underwent a contrast-enhanced first-pass and 3D MR angiography (MRA) of the aorta and its main branches. All examinations were on a clinical 3 Tesla MR system (Siemens Healthcare, Erlangen, Germany). The clinical dose of 0.1 mmol/kg was administered in both probes. First, a time-resolved MRA (TWIST) was acquired during the first-pass to assess the arrival and washout of the contrast agent bolus. Subsequently, a high-resolution 3D MRA sequence (3D T1 FLASH) was acquired. Signal-to-noise ratios (SNRs) and contrast-to-noise ratios (CNRs) were calculated for all sequences. Results. The elastin-specific MR probe and the extravascular imaging agent (gadobutrol) enable high-quality MR angiograms in all animals. During the first-pass, the probes demonstrated a comparable peak enhancement (300.6 ± 32.9 vs. 288.5 ± 33.1, p>0.05). Following the bolus phase, both agents showed a comparable intravascular enhancement (SNR: 106.7 ± 11 vs. 102.3 ± 5.3; CNR 64.5 ± 7.4 vs. 61.1 ± 7.2, p>0.05). Both agents resulted in a high image quality with no statistical difference (p>0.05). Conclusion. The novel elastin-specific molecular probe enables the performance of first-pass and late 3D MR angiography with an intravascular contrast enhancement and image quality comparable to a clinically used extravascular contrast agent.

scholarly journals Three-dimensional MR pulmonary perfusion imaging and angiography with an injection of a new blood pool contrast agent B-22956/1

2001 ◽  
Vol 14 (4) ◽  
pp. 425-432 ◽  
Author(s):  
Jie Zheng ◽  
James Carr ◽  
Katherine Harris ◽  
Mark B. Saker ◽  
Friedrich M. Cavagna ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Perfusion Imaging ◽  
Three Dimensional ◽  
Blood Pool ◽  
Pulmonary Perfusion ◽  
Blood Pool Contrast Agent

scholarly journals PEG-modified gadolinium nanoparticles as contrast agents for in vivo micro-CT

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Charmainne Cruje ◽  
P. Joy Dunmore-Buyze ◽  
Eric Grolman ◽  
David W. Holdsworth ◽  
Elizabeth R. Gillies ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Contrast Agents ◽  
Soft Tissues ◽  
Three Dimensional ◽  
Blood Pool ◽  
Micro Ct ◽  
Micro Computed Tomography ◽  
Poly Ethylene

AbstractVascular research is largely performed in rodents with the goal of developing treatments for human disease. Micro-computed tomography (micro-CT) provides non-destructive three-dimensional imaging that can be used to study the vasculature of rodents. However, to distinguish vasculature from other soft tissues, long-circulating contrast agents are required. In this study, we demonstrated that poly(ethylene glycol) (PEG)-coated gadolinium nanoparticles can be used as a vascular contrast agent in micro-CT. The coated particles could be lyophilized and then redispersed in an aqueous solution to achieve 100 mg/mL of gadolinium. After an intravenous injection of the contrast agent into mice, micro-CT scans showed blood pool contrast enhancements of at least 200 HU for 30 min. Imaging and quantitative analysis of gadolinium in tissues showed the presence of contrast agent in clearance organs including the liver and spleen and very low amounts in other organs. In vitro cell culture experiments, subcutaneous injections, and analysis of mouse body weight suggested that the agents exhibited low toxicity. Histological analysis of tissues 5 days after injection of the contrast agent showed cytotoxicity in the spleen, but no abnormalities were observed in the liver, lungs, kidneys, and bladder.

Sign in / Sign up

Export Citation Format

Share Document